FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1455-1456 November 7, 1996 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The identification of BRCA1 as the first gene for susceptibility to breast and ovarian cancer was an important step toward a better understanding of the biology of these cancers.¹ This advance should lead to new therapies, but for now it provides a unique opportunity to develop new strategies for early detection and prevention. The intense attention in the media to this breakthrough has caused many highly motivated women with family histories of cancer to seek counseling about their risks and options for prevention. It is no longer unusual for women with newly diagnosed breast cancer to seek genetic testing before . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Maron, B. J., Moller, J. H., Seidman, C. E., Vincent, G. M., Dietz, H. C., Moss, A. J., Towbin, J. A., Sondheimer, H. M., Pyeritz, R. E., McGee, G., Epstein, A. E. (1998). Impact of Laboratory Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Diseases: Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome : A Statement for Healthcare Professionals From the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. Circulation 98: 1460-1471 [Full Text]